And, generally, physicians are less likely to accept chemotherapy for modest survival benefit
Among patients participating in a chemotherapy drug trial, there is substantial variation in preferences regarding length of survival benefits that justify undergoing chemotherapy, according to a study published online March 21 in Cancer.
Ines Vaz-Luis, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a survey of breast cancer patients participating in a phase 3, randomized controlled adjuvant chemotherapy trial. At 18 months, the researchers assessed the survival benefit needed to justify six months of chemotherapy. Physicians who had enrolled patients in the study received a parallel survey.
Read Full Article Here >>